FTSE MIB
26.315,09 +108,42 (+0,41%) Dow Jones
32.432,08 +194,55 (+0,60%) Nasdaq
11.768,84 -55,12 (-0,47%) Nikkei 225
27.518,25 +41,38 (+0,15%) Petrolio
72,78 -0,03 (-0,04%) Bitcoin EUR
25.030,62 -665,57 (-2,59%)
Bristol-Myers Squibb Company (BMY)
Preborsa:
| Chiusura precedente | 67,68 |
| Aperto | 68,09 |
| Denaro | 0,00 x 900 |
| Lettera | 0,00 x 1200 |
| Min-Max giorno | 68,01 - 68,82 |
| Intervallo di 52 settimane | 65,28 - 81,44 |
| Volume | |
| Media Volume | 8.254.790 |
| Capitalizzazione | 143,172B |
| Beta (5 anni mensile) | 0,45 |
| Rapporto PE (ttm) | 23,07 |
| EPS (ttm) | 2,95 |
| Prossima data utili | 27 apr 2023 |
| Rendimento e dividendo (forward) | 2,28 (3,35%) |
| Data ex dividendo | 05 gen 2023 |
| Stima target 1A | 81,09 |
- GlobeNewswire
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
- GlobeNewswire
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Brist
- GlobeNewswire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol M
